Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ribavirin/pharmacology"'
Autor:
Sébastien Lhomme, Olivier Marion, Nicolas Carrere, Florence Abravanel, Marion Migueres, Nassim Kamar, Mélanie Pucelle, Pierre Delobel, Martine Dubois, Bertrand Suc, Mary Requena, Manon Nayrac, Jean-Marie Peron, Jacques Izopet
Publikováno v:
Gut
Gut, BMJ Publishing Group, 2020, 69 (5), pp.901-910. ⟨10.1136/gutjnl-2019-319004⟩
Gut, BMJ Publishing Group, 2020, 69 (5), pp.901-910. ⟨10.1136/gutjnl-2019-319004⟩
ObjectiveHepatitis E virus (HEV), one of the most common agent of acute hepatitis worldwide, is mainly transmitted enterically, via contaminated water for HEV genotypes 1 (HEV1) and HEV2, or by eating raw or undercooked infected meat for HEV genotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56835005e2457dc7227b0e4cfe93e33f
https://pubmed.ncbi.nlm.nih.gov/31915238
https://pubmed.ncbi.nlm.nih.gov/31915238
Autor:
Marta Grandal, Álvaro Mena, Manuel Delgado, Berta Pernas, Ana Mariño, Hortensia Álvarez, Nieves Valcarce, Ana B. Pérez, Eva Poveda, Andrés Tabernilla, Ángeles Castro-Iglesias
Publikováno v:
RUC. Repositorio da Universidade da Coruña
instname
instname
[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A region is mainly focused on patients with hepatitis C virus (HCV) ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aad7b092ae15cd93d4287eb797adb38
https://hdl.handle.net/2183/20798
https://hdl.handle.net/2183/20798
Autor:
Maria Francesca Donato, François Helle, Francesco Negro, Massimo Levrero, Fabien Zoulim, Barbara Testoni, David Durantel, Fanny Lebossé, Judith Fresquet
Publikováno v:
Gut
Gut, BMJ Publishing Group, 2016, 65 (4), pp.672-682. ⟨10.1136/gutjnl-2014-309011⟩
Gut, Vol. 65, No 4 (2016) pp. 672-682
Gut, BMJ Publishing Group, 2016, 65 (4), pp.672-682. ⟨10.1136/gutjnl-2014-309011⟩
Gut, Vol. 65, No 4 (2016) pp. 672-682
International audience; OBJECTIVES: Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and dire
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::587b3ca40bccc062c997fb8fe9f62898
https://pubmed.ncbi.nlm.nih.gov/26082258
https://pubmed.ncbi.nlm.nih.gov/26082258
Autor:
Elefsiniotis, I. S., Petrocheilou, A., Scarmeas, N., Ketikoglou, I., Pantazis, K. D., Toutouza, M., Tsianos, E. V.
OBJECTIVES: To evaluate the alterations of serum procalcitonin (PCT) levels in patients with chronic hepatitis C during pegylated interferon-alpha (PEG-IFNa) plus ribavirin (RIB) treatment and to correlate them with clinical and virological outcomes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10561::f09ec35f2811c025aee4700c4b815349
http://olympias.lib.uoi.gr/jspui/handle/123456789/18347
http://olympias.lib.uoi.gr/jspui/handle/123456789/18347